Moneycontrol
Get App
Last Updated : Dec 20, 2017 02:59 PM IST | Source: CNBC-TV18

Regulatory risk is only risk that business faces: Lasa Supergenerics

In an interview with CNBC-TV18, Omkar P Herlekar, MD of Lasa Supergenerics spoke about the latest happenings in his company and sector. The company manufactures benzimidazole class of active pharmaceutical ingredients (APIs).

CNBC TV18 @moneycontrolcom

In an interview with CNBC-TV18, Omkar P Herlekar, MD of Lasa Supergenerics spoke about the latest happenings in his company and sector.

The company manufactures benzimidazole class of active pharmaceutical ingredients (APIs).

Capex will be happening on a proportionate basis, he said.

Close

APIs are bound by foods and drug administration (FDA) regulations and the process to get approvals is tedious, he added.

According to him, regulatory risk is the only risk that the business faces.

Right now, we are registered with the Indian Drug Agency and we have filed our DMFs in various countries which includes Europe also, said Herlekar.

For full interview, watch accompanying video...

Exclusive offer: Use code "BUDGET2020" and get Moneycontrol Pro's Subscription for as little as Rs 333/- for the first year.

First Published on Dec 20, 2017 02:53 pm

tags #Business

Sections
Follow us on